A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
Authors
Keywords
-
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 134, Issue 3, Pages 1149-1159
Publisher
Springer Nature
Online
2012-07-05
DOI
10.1007/s10549-012-2126-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting EGFR in Triple Negative Breast Cancer
- (2012) Naoto T. Ueno et al. Journal of Cancer
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer
- (2011) V. Hirsh Current Oncology
- p53 Status Identifies Two Subgroups of Triple-negative Breast Cancers with Distinct Biological Features
- (2011) E. Biganzoli et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
- (2010) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR signaling in breast cancer: Bad to the bone
- (2010) John Foley et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer
- (2009) M. D. Green et al. ANNALS OF ONCOLOGY
- Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
- (2009) B. Corkery et al. ANNALS OF ONCOLOGY
- Triple-negative breast cancer--current status and future directions
- (2009) O. Gluz et al. ANNALS OF ONCOLOGY
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer
- (2009) D. Zhang et al. CLINICAL CANCER RESEARCH
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- (2009) Jorg Hartmann et al. CURRENT DRUG METABOLISM
- Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer
- (2009) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype
- (2008) D. Sarrio et al. CANCER RESEARCH
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now